Business
REG - Novacyt S.A. - Resolution re. Lab 21 HSE Prosecution
REG - Novacyt S.A. - Resolution re. Lab 21 HSE Prosecution
About this update from Novacyt Sas
RNS Number : 1475Z Novacyt S.A. 12 September 2025 Novacyt S.A.("Novacyt", the "Company" or the "Group")Resolution re. Lab 21 HSE ProsecutionParis, France, and Manchester, UK - 12 September 2025 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, provides an update with regards to the Health and Safety Executive ("HSE") prosecution first announced on 21 January 2025.On 11 September 2025, a sentencing hearing took place in respect of legal proceedings brought against Lab 21 Healthcare Ltd ("Lab 21"), a non-trading subsidiary of Novacyt, in relation to Lab 21's site based at Axminster, Devon for the use of biological agents at the site. As announced on 18 March 2025, Lab 21 pleaded guilty at Exeter Magistrates Court to health and safety charges relating to the historical operation at the site, between June 2018 and April 2019. The court granted full recognition for an early guilty plea with Lab 21 being ordered to pay a fine of £52,000.This fine will be paid from existing cash resources and does not materially affect the Group financial position.This now concludes this process, with no further liability or legal action expected in relation to this case.ContactsNovacyt SAhttps://novacyt.com/investorsLyn Rees, Chief Executive Officer Via Walbrook PRSteve Gibson, Chief Financial Officer SP Angel Corporate Finance LLP (Nominated Adviser and Broker)+44 (0)20 3470 0470Matthew Johnson / Charlie Bouverat (Corporate Finance)Vadim Alexandre / Rob Rees (Corporate Broking)Deutsche Numis (Joint Broker)+44 (0)20 7260 1000Freddie Barnfield / Duncan Monteith / Michael PalserAllegra Finance (French Listing Sponsor)Rémi Durgetto / Yannick Petit +33 (1) 42 22 10 10 [email protected] / [email protected] PR (Financial PR & IR)Paul McManus / Lianne ApplegarthAlice Woodings+44 (0)20 7933 8780 or [email protected]+44 (0)7980 541 893 / +44 (0)7584 391 303 +44 (0)7407 804 654About Novacyt Group (www.novacyt.com)Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seam...